Tamura et al., 2019 - Google Patents
Immunotherapy for multiple myelomaTamura et al., 2019
View HTML- Document ID
- 123911086376881565
- Author
- Tamura H
- Ishibashi M
- Sunakawa M
- Inokuchi K
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Despite therapeutic advances over the past decades, multiple myeloma (MM) remains a largely incurable disease with poor prognosis in high-risk patients, and thus new treatment strategies are needed to achieve treatment breakthroughs. MM represents various forms of …
- 206010035226 Plasma cell myeloma 0 title abstract description 190
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kailayangiri et al. | Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers | |
| Peterson et al. | Recent advances and challenges in cancer immunotherapy | |
| Tamura et al. | Immunotherapy for multiple myeloma | |
| Martín-Antonio et al. | Natural killer cells: angels and devils for immunotherapy | |
| Roex et al. | Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: an update of the pivotal clinical trial data | |
| Gonzalez-Rodriguez et al. | NK cells in the treatment of hematological malignancies | |
| Kleber et al. | BCMA in multiple myeloma—a promising key to therapy | |
| Bonello et al. | Therapeutic monoclonal antibodies and antibody products: current practices and development in multiple myeloma | |
| Todorovic et al. | CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings | |
| Castella et al. | Immunotherapy: a novel era of promising treatments for multiple myeloma | |
| Franssen et al. | Resistance mechanisms towards CD38− directed antibody therapy in multiple myeloma | |
| Kocoglu et al. | The role of immunotherapy in multiple myeloma | |
| Haibe et al. | Resisting resistance to immune checkpoint therapy: a systematic review | |
| Modi et al. | Immunotherapy for diffuse large B-cell lymphoma: current landscape and future directions | |
| Zahavi et al. | Targeting multiple receptors to increase checkpoint blockade efficacy | |
| Petty et al. | Chimeric antigen receptor cell therapy: overcoming obstacles to battle cancer | |
| Mulder et al. | Targeting the immune microenvironment in lymphomas of B-cell origin: from biology to clinical application | |
| Noh et al. | Immunotherapy in hematologic malignancies: emerging therapies and novel approaches | |
| Klampatsa et al. | Chimeric antigen receptor (CAR) T cell therapy for malignant pleural mesothelioma (MPM) | |
| Hao et al. | The role of T cell immunotherapy in acute myeloid leukemia | |
| Gbolahan et al. | Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment | |
| Al-Hujaily et al. | Development of novel immunotherapies for multiple myeloma | |
| Nishida | Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review | |
| Broos et al. | Single domain antibody-mediated blockade of programmed death-ligand 1 on dendritic cells enhances CD8 T-cell activation and cytokine production | |
| Bachiller et al. | Natural killer cells in immunotherapy: are we nearly there? |